Skip to content

Latest Post

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss Manipur Liquor Tragedy: Toll Hits 15 as 300+ Treated for Suspected Methanol Poisoning
  • Sat. Nov 21st, 2026

  • Home
  • About Us
  • Author
  • Contact Us
Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb

The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here…

Clinical Trials

India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial

November 21, 2026 Simone Lamb

A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.

Clinical Trials

Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients

November 21, 2026 Simone Lamb

PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned…

Clinical Trials

GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss

November 21, 2026 Simone Lamb

Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with…

Healthcare Services

Manipur Liquor Tragedy: Toll Hits 15 as 300+ Treated for Suspected Methanol Poisoning

November 21, 2026 Simone Lamb

Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we…

Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb

The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn…

Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb

The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.

Clinical Trials

India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial

November 21, 2026 Simone Lamb

A CDSCO expert panel recommended a Phase I trial of Indian Immunologicals' live attenuated Zika vaccine, developed with Griffith University and funded by ICMR.

Clinical Trials

Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients

November 21, 2026 Simone Lamb

PMV Pharmaceuticals' rezatapopt produced a 48% response rate in platinum-resistant ovarian cancer with TP53 Y220C in the pivotal PYNNACLE trial, with an FDA filing planned for Q1 2027.

Clinical Trials

GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss

November 21, 2026 Simone Lamb

Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with most benefits holding after adjusting…

Healthcare Services

Manipur Liquor Tragedy: Toll Hits 15 as 300+ Treated for Suspected Methanol Poisoning

November 21, 2026 Simone Lamb

Up to 15 people have died and more than 300 have sought care in Imphal after drinking spurious liquor in Manipur's Chandel district. What we know, and how methanol poisoning…

Oncology

Daraxonrasib in First-Line Pancreatic Cancer: 60.7% Response With Chemotherapy

November 20, 2026 Simone Lamb

Updated RMC-GI-102 data at ENA 2026 show Rasonque (daraxonrasib) plus gemcitabine and nab-paclitaxel achieved a 60.7% response rate, 12.8-month PFS and 76.6% one-year survival in untreated metastatic pancreatic cancer.

Pharmaceutical

Efsubaglutide Alfa: Innogen’s $1 Billion GLP-1 Deal Takes China’s Long-Acting Drug to Emerging Markets

November 20, 2026 Simone Lamb

Innogen has licensed its China-approved GLP-1 efsubaglutide alfa to Arcera for Africa, Eastern Europe, Latin America and the Middle East in a deal worth over $1 billion.

FDA Approvals

Sogroya for Turner Syndrome: FDA Approves First Weekly Growth Hormone for Girls With TS

November 20, 2026 Simone Lamb

FDA approves once-weekly Sogroya for growth failure in Turner syndrome. REAL8 data, side effects, limits and what it means for families.

Clinical Trials

ERAS-0015 Pancreatic Cancer Pill Shrinks Tumours in 44% of Pretreated Patients

November 20, 2026 Simone Lamb

Erasca's oral pan-RAS molecular glue ERAS-0015 produced a 44% confirmed response rate in pretreated KRAS-mutant pancreatic cancer, 69% in G12D/G12V tumours, in Phase 1.

Pharmaceutical

Ozempic and Dementia: What a New Science Review Says About GLP-1 Drugs and the Brain

November 20, 2026 Simone Lamb

A Science review weighs whether Ozempic, Wegovy and Mounjaro protect the brain. Observational data look promising, but Alzheimer trials were negative. What we know.

Posts pagination

1 2 … 36

You missed

Pharmaceutical

Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label

November 21, 2026 Simone Lamb
Clinical Trials

India’s First Zika Vaccine Wins CDSCO Panel Nod for Phase I Trial

November 21, 2026 Simone Lamb
Clinical Trials

Rezatapopt Ovarian Cancer Data: p53 Pill Shrinks Tumours in 48% of Platinum-Resistant Patients

November 21, 2026 Simone Lamb
Clinical Trials

GLP-1 Heart Failure Study: Semaglutide and Tirzepatide Remodel Weak Hearts Beyond Weight Loss

November 21, 2026 Simone Lamb

Proudly powered by WordPress | Theme: NewsTwenty by Themeansar.

  • Home
  • About Us
  • Author
  • Contact Us